ADMA Biologics (NASDAQ:ADMA) Stock Price Up 4.6% – Here’s What Happened

Shares of ADMA Biologics Inc (NASDAQ:ADMA) rose 4.6% during mid-day trading on Monday. The stock traded as high as $9.74 and last traded at $9.8090. Approximately 992,204 shares traded hands during trading, a decline of 77% from the average daily volume of 4,236,085 shares. The stock had previously closed at $9.38.

Analysts Set New Price Targets

ADMA has been the subject of several recent analyst reports. Zacks Research upgraded shares of ADMA Biologics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, September 2nd. Raymond James Financial initiated coverage on shares of ADMA Biologics in a research note on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 target price for the company. Mizuho cut their price target on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Monday, September 14th. Three equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $18.67.

ADMA Biologics Stock Performance

The firm’s fifty day simple moving average is $9.34 and its 200 day simple moving average is $9.49. The company has a market capitalization of $2.23 billion, a PE ratio of 14.23 and a beta of 0.78. The company has a debt-to-equity ratio of 0.49, a current ratio of 6.97 and a quick ratio of 3.81.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.16. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The business had revenue of $124.39 million during the quarter, compared to analyst estimates of $125.34 million. During the same quarter last year, the business posted $0.14 EPS. The company’s revenue was up 2.0% on a year-over-year basis. On average, research analysts predict that ADMA Biologics Inc will post 0.78 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Western Wealth Management LLC purchased a new stake in ADMA Biologics in the 1st quarter worth $31,000. Rockefeller Capital Management L.P. lifted its holdings in ADMA Biologics by 60.7% during the fourth quarter. Rockefeller Capital Management L.P. now owns 4,485 shares of the biotechnology company’s stock valued at $82,000 after purchasing an additional 1,694 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in shares of ADMA Biologics in the second quarter valued at about $42,000. Quantbot Technologies LP acquired a new stake in shares of ADMA Biologics in the second quarter valued at about $51,000. Finally, Nykredit A S purchased a new stake in shares of ADMA Biologics during the second quarter worth about $59,000. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and marketing plasma-derived biologic products for patients with compromised or inadequate immune systems. The company’s activities include operating plasma collection centers, sourcing human plasma, and producing specialized immunoglobulin therapies.

ADMA’s marketed products include ASCENIV, an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency disease; BIVIGAM, an intravenous immune globulin for primary humoral immunodeficiency; and Nabi-HB, a hepatitis B immune globulin used to provide protection against hepatitis B infection in certain clinical settings.